The first in Oklahoma to offer this treatment technology
TULSA, OK – April 5, 2022 – Oklahoma Cancer Specialists and Research Institute (OCSRI), the region’s most comprehensive cancer care provider, has added the newest state-of-the-art radiation treatment technology for precision treatments. This further protects the vital organs of cancer patients undergoing treatment. OCSRI is the first in Oklahoma to provide this improved treatment method.
The American Cancer Society estimates that in Oklahoma alone there will be more than 23,000 new cancer cases in 2022. OCSRI’s investments in cutting-edge equipment allow Oklahomans to receive world-class care without the burdens of having to travel out of state.
For nearly five decades, Elekta has been a global leader in precision radiation medicine. OCSRI is proud to be a national reference site for Elekta, offering a broad range of state-of-the-art hardware and software products to expand radiation therapy options for patients in Northeast Oklahoma.
A medical linear accelerator or LINAC uses high-energy x-rays to target the tumor and destroy the cancer cells. OCSRI pairs Elekta’s latest LINAC technology with C-Rad’s surface guided radiation therapy (SGRT) solution. Together, these technologies help deliver radiation therapy at speed and with precision ensuring the best possible treatment outcomes.
“Our new facial and body surface recognition programs allow patients to receive more customized treatment and more accurate delivery of the customized radiation,” said Grenville Jones, MD, OCSRI Radiation Oncologist.” It’s extremely reassuring that the artificial intelligence program will turn the radiation delivery off if it detects a significant deviation from the original plan.”
Advanced technology such as SGRT allows oncologists to be more accurate than ever and ensures patients that they are receiving safe, world-class treatment.
Access to advanced treatment technologies and preventative care is vital to the health of our community. OCSRI would like to remind Oklahomans about the importance of preventative screenings. Cancer screenings – such as breast cancer and cervical cancer screenings –were down nearly 90% during the pandemic according to the CDC. Screening has the potential to detect cancerous or precancerous lesions in their earliest stages when they are most treatable, and before symptoms appear. Delays in screening lead to later-stage diagnosis and a need for more aggressive treatments.
To learn more about advanced technologies and treatments available, visit ocsri.org.
OCSRI is a leader and patient-centric oncology institute providing renowned multidisciplinary care empowered by progressive clinical research. As a physician-owned network rooted in Tulsa, Oklahoma, we are driven by compassionate relationships and a commitment to excellence. With a team of nationally accredited specialists, we provide personalized treatment, transparent counsel and advanced technology to deliver the most effective care possible.
C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor and, at the same time, to protect healthy tissue from unwanted exposure. Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient’s motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy. C-RAD monitors the patient’s motion without the use of tattoos or additional imaging dose to deliver the highest level of patient safety and comfort.
For almost five decades, Elekta has been a leader in precision radiation medicine. Our more than 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter, Facebook and LinkedIn.